Vesalio launches pVasc Thrombectomy System in the U.S. for peripheral occlusions

PLANO, Texas, Sept. 4, 2024 /PRNewswire/ -- Vesalio announces the U.S. commercialization of pVasc™ Thrombectomy System for non-surgically removing peripheral occlusions. pVasc targets the full range of embolisms from soft, acute clots to fibrin-rich, calcified ones, enabling a fast and safe removal. Its unique Drop Zone™ technology traps, retains and securely removes thrombus to restore flow in patients suffering from acute limb ischemia (ALI) and other conditions related to peripheral artery disease (PAD).

“Given the complicated health history of patients with ALI, physicians often face the challenge of delivering devices through highly diseased arteries and working in small, stenotic vessels,” noted Dr. Frank Arko, Chief, Vascular and Endovascular Surgery and Co-Director of the Aortic Institute at Carolinas Medical Center, Sanger Heart and Vascular Institute, Charlotte, North Carolina. “pVasc has a low profile and excellent deliverability, making it an especially valuable tool when access is difficult or when working in arteries below the knee.”

PAD affects 10 – 12 million adults in the U.S. aged 40 and older, increasing their risk of amputation, heart attack, stroke, and death.1 Each year, approximately 185,000 amputations are performed in the U.S., with more than 2 million people currently living with an amputation.According to the American Heart Association, nearly half of people 65 and older who underwent a limb amputation due to PAD died within a year of surgery.3

Sign up for Blog Updates